FDA Commissioner Marty Makary announced a new policy to publicly release redacted complete response letters (CRLs) simultaneously with drug sponsors receiving them. This landmark decision aims to increase agency transparency and credibility regarding drug approval decisions. The initiative follows longstanding calls from the public and scientific communities to provide insight into the FDA’s regulatory decisions and to foster trust in the drug review process.